Navigation Links
U.S. Genomics Inc. Receives $4.5 Million Investment from BD
Date:9/23/2008

- Enters Strategic Collaboration for Development of Novel Infectious

Disease Diagnostic Platform -

WOBURN, Mass., Sept. 23 /PRNewswire/ -- U.S. Genomics today announced it has received a $4.5 million equity investment from BD (Becton, Dickinson and Company) and that the companies have entered into a strategic collaboration for development of a novel infectious disease diagnostic platform. The collaboration will focus on application of U.S. Genomics' DirectLinear Analysis(TM) technology (DLA) for the detection of a wide range of infectious organisms in a single molecular diagnostic test. A diagnostic platform based on DLA has the potential to provide information to physicians concerning pathogen identity, virulence and drug resistance within hours, as opposed to the multi-day techniques such as culturing, plating, and staining that are done today.

U.S. Genomics has invested in excess of $50 million in DLA technology, which integrates novel labeling strategies, advanced microfluidics and optical engineering to enable pathogens to be identified by rapidly analyzing individual DNA molecules present in a clinical sample. The technology is capable of simultaneously detecting a broad range of infectious organisms in a single diagnostic test. A diagnostic test based on DLA has the potential to provide clinicians and doctors' information important for patient health, such as which drugs a specific pathogen may be resistant to, and which drugs could be used for most effective patient treatment.

"We are very pleased to enter into this strategic relationship with BD," said John J. Canepa, U.S. Genomics' CEO. "BD is the clear market leader in clinical microbiology and their deep experience in product development is an ideal complement to our innovative DLA technology and strong research team. We share the goal of establishing a new, faster, more accurate capability for microbial diagnostics, based on genotype, leading to more
'/>"/>

SOURCE U.S. Genomics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
4. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
5. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
6. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
9. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
10. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Prairie Heart Institute of Illino...ly awarded two statuettes at the first-ever CLIO H.... The CLIO Healthcare Awards recognizes creative e...sing industry and is an extension of the CLIO Awar...etitions for advertising, design and interactive. ...
(Date:12/1/2009)...wswire-FirstCall/ -- Palatin Technologies, Inc. (N...ent and Trademark Office has issued U.S. Patent No...nstructs." The claims in the issued patent cover ...tic peptide receptor A (NPRA), including PL-3994, ... "Our natriuretic compounds, including PL-3994, ad...
(Date:12/1/2009)...wswire-FirstCall/ -- Medizone International, Inc. ... tests involving its proprietary AsepticSure(TM) t...nation barriers, this time with two very different...d Bacillis subtilis. These results clearly establi...al technology. "The implications of a 6.7 log redu...
(Date:12/1/2009)...tarian organizations will collaborate in comprehen...r technologies. Their shared efforts will begin in... , Dallas, TX (PRWEB) Dec...randum of Understanding, Mercy Ships and MediSend ...p develop sustainable infrastructure in hospitals ...
Breaking Biology Technology:Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3
...by Investigators from Tumor Institute in ...ell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC...ology has published the results of an innovative s... dose Zevalin(R) ([90Y]-ibritumomab tiuxetan),foll...tients (median age 62,years) with relapsed/refract...
...today announced the launch of the Mattel UCLA Nano...of personalized medicine for children, including t...s one of the world,s first dedicated solely to nan...op a nanopediatrics program? Because children are ...an-in-chief of Mattel Children,s Hospital and foun...
...ms Inc.,(AMEX: PLC ) today announced that it has ...e that would demonstrate its ability to regain,com...ordingly, the company,anticipates that its common ...hange in the next several weeks, and begin to trad...viously announced, PLC received a notice of failur...
Other Biology Technology:High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 2High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 3High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 4High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 5Mattel Children's Hospital UCLA launches program in nanopediatrics 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 3
(Date:11/30/2009)...CLEMSON Clemson University researchers Ron Falta ...nmental Protection Agency grant to study the safe ... located deep below the earth,s surface. , With ... believed to be the leading cause of global warmin...promising alternatives for reducing emissions usin...
(Date:11/30/2009)...his release is available in German . , The ...borative Research Centres as of 1 January 2010. Th...ts Committee in Bonn. The new centres will initial...llion. In addition, 20 percent overhead funding fo...oject. The centres, research topics range from mod...
(Date:11/30/2009)...e Editors of The Journal of Experimental Biology ...m Centre National de la Recherche Scientifique (CN...he winner of this year,s JEB Outstanding Paper P...utstanding achievement and is intended to encourag... Editor-in-Chief, and adds that ,we truly appreci...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Mothers immune system may block fetal treatments for blood diseases 9590 1Mothers immune system may block fetal treatments for blood diseases 9590 2Mothers immune system may block fetal treatments for blood diseases 9590 3New nanolaser key to future optical computers and technologies 13581 1New nanolaser key to future optical computers and technologies 13581 2New nanolaser key to future optical computers and technologies 13581 3CAS REGISTRY 28SM 29 the Global Standard for Chemical Research Approaches 50 Millionth Registration Milestone 54595 1CAS REGISTRY 28SM 29 the Global Standard for Chemical Research Approaches 50 Millionth Registration Milestone 54595 2
...ernational, Inc. (OTC Bulletin Board: BKYI), a lea...ireless public safety solutions, announced today t...land Security Investor Conference to be held durin...g BIO-key,s participation at the conference are pr...s Homeland Security Investor Conference: To be he...
...se Biometrics came in,first place in the global SI...d Mobile Congress - the world,s largest event for ...solution is based on Precise Match-on-SIM(TM) and,...ition and mobile phones. , SIMagine is a globa... for,mobile communication and Java cards. The comp...
...stranded seabirds washed up on the shores of Monte...oated with an unknown substance. After an intensiv...ive "red tide" bloom of marine algae had produced ...ral waterproofing from the birds, feathers. , Th...imilar events may have gone undetected in the past...
Other Biology News:BIO-key(R) Announces Conference Schedule 2Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress 2Study links seabird deaths to soap-like foam produced by red-tide algae 2
... is critical to the maintenance of appropriate lev...rtant and diverse as those involved in cellular me...presentation, modulation of cell surface receptors...ption, and signalling factors. The ubiquitin-prote...
... is critical to the maintenance of appropriate lev...rtant and diverse as those involved in cellular me...presentation, modulation of cell surface receptors...ption, and signalling factors. The ubiquitin-prot...
...A modified digital scanner serves as the spot-pick...ive standard rack positions on the tray, leaving s...g two racks.,The software allows for manual select...gel image. The individual x,y-coordinates, togethe...
Telomerase ELISA Assay Kit, TRAPEZE from CHEMICON
Biology Products: